title: [Strategy in advanced castration-resistant prostate cancer].
abstract: If androgen deprivation, chemical with LH-RH analogs or surgical with bilateral orchiectomy, still remains the stone edge of treatment of prostate cancer, in the metastatic setting, this hormonosensitivity, most of the time long, finally move on in hormonal-failure. If rare changes in the therapeutic strategy have been achieved in this setting since 2004 and the arrival of docetaxel, it is the global perception of the disease that has been modified and the definition of one specific entity: the castrate-resistant prostate cancer. This new definition and the changes of design and end-points of clinical trials testing new agents with strong recruitment during the past years have conducted to a real revolution in the management of castrate-refractory prostate cancer. The place of secondary hormonal manipulations, such as withdrawal of the anti-androgen, oestrogen or ketoconazole, still exists for a selected group of patients. In case of aggressive disease and symptoms, chemotherapy should be selected, docetaxel, in a three weeks schedule, and may be combined with Estracyt. It is time to consider the revolution of the post-chemotherapy setting with the arrival of two new drugs ; a cytotoxic one, the cabazitaxel and hormonal for the second one, the abiraterone acetate. The place of the immunotherapy with the sipuleucel-T may be more difficult to precise, especially in Europe, even if it has been finally indicated in the United States in the metastatic setting. Concerning bone metastasis, zoledronic acid was during a long time the only bone-targeted agent, effective in reducing the incidence of skeletal related events, and was recently exceeded by the denosumab, an anti-RANK ligand. Finally, let us hope that other changes will be achieved in the near future, with the cabazitaxel-docetaxel confrontation in the first-line setting, and the introduction of the abiraterone acetate before chemotherapy with docetaxel, already tested in ongoing trials.
authors.affiliation: CHU de Bordeaux, hôpital Saint-André, service d'oncologie médicale, 1, rue Jean-Burguet, 33075 Bordeaux, France. marine.gross-goupil@chu-bordeaux.fr
authors.forename: Marine
authors.initials: M
authors.lastname: Gross-Goupil
authors.forename: Sophie
authors.initials: S
authors.lastname: Roca
authors.forename: Gilles
authors.initials: G
authors.lastname: Pasticier
authors.forename: Alain
authors.initials: A
authors.lastname: Ravaud
mesh_terms: D000069501:Abiraterone Acetate; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000730:Androstadienes / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000517:prevention & control / Q000556:secondary; D019496:Cancer Vaccines / Q000627:therapeutic use; D000069448:Denosumab; D004164:Diphosphonates / Q000627:therapeutic use; D000077143:Docetaxel; D004961:Estramustine / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D043823:Taxoids / Q000627:therapeutic use; D014020:Tissue Extracts / Q000627:therapeutic use; D000077211:Zoledronic Acid
chemical_list: D000726:Androgen Antagonists; D000730:Androstadienes; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D019496:Cancer Vaccines; D004164:Diphosphonates; D007093:Imidazoles; D043823:Taxoids; D014020:Tissue Extracts; D000077143:Docetaxel; D004961:Estramustine; D000069448:Denosumab; C552428:cabazitaxel; D000077211:Zoledronic Acid; C511774:sipuleucel-T; D000069501:Abiraterone Acetate